Orexo AB - ESG Rating & Company Profile powered by AI
Other companies in the rating industry group for Orexo AB are displayedin the table. This assessment of Orexo AB uses intelligence from across the web and also from public filings by Orexo AB. The webpage displays a free Sustainability analysis for Orexo AB.
Orexo AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.1; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.1
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 18 | Pacific Biosciences of California Inc | 8.2 | High |
| 18 | Valneva SE | 8.2 | High |
| 36 | Orexo AB | 8.1 | High |
| 36 | Adcock Ingram Holdings Ltd | 8.1 | High |
| 36 | Alkem Laboratories Ltd | 8.1 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Orexo AB have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Orexo AB disclose current and historical energy intensity?
Sign up for free to unlockDoes Orexo AB report the average age of the workforce?
Sign up for free to unlockDoes Orexo AB reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Orexo AB disclose its ethnicity pay gap?
Sign up for free to unlockDoes Orexo AB disclose cybersecurity risks?
Sign up for free to unlockDoes Orexo AB offer flexible work?
Sign up for free to unlockDoes Orexo AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Orexo AB disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Orexo AB conduct supply chain audits?
Sign up for free to unlockDoes Orexo AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Orexo AB conduct 360 degree staff reviews?
Sign up for free to unlockDoes Orexo AB disclose the individual responsible for D&I?
Sign up for free to unlockDoes Orexo AB disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Orexo AB disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Orexo AB disclose water use targets?
Sign up for free to unlockDoes Orexo AB have careers partnerships with academic institutions?
Sign up for free to unlockDid Orexo AB have a product recall in the last two years?
Sign up for free to unlockDoes Orexo AB disclose incidents of discrimination?
Sign up for free to unlockDoes Orexo AB allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Orexo AB issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Orexo AB disclose parental leave metrics?
Sign up for free to unlockDoes Orexo AB disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Orexo AB disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Orexo AB disclose the pay ratio of women to men?
Sign up for free to unlockDoes Orexo AB support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Orexo AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Orexo AB reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Orexo AB involved in embryonic stem cell research?
Sign up for free to unlockDoes Orexo AB disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Orexo AB disclose its waste policy?
Sign up for free to unlockDoes Orexo AB report according to TCFD requirements?
Sign up for free to unlockDoes Orexo AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Orexo AB disclose energy use targets?
Sign up for free to unlockDoes Orexo AB disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Orexo AB have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Orexo AB
These potential risks are based on the size, segment and geographies of the company.
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.